N/A N=20 Endovascular Repair for the Descending Thoracic Aorta
Aorta Thoracic; Traumatic Rupture
Primary: Number of Participants With Major Adverse Events — 0 number of serious adverse events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Study to Determine if the Valiant Stent Graft is Safe and Effective in Treating Patients Who Have a Blunt Thoracic Aortic Injury
Blunt Thoracic Aortic Injury
Primary: All-cause Mortality Within 30-days of the Index Procedure — 4 participants
N/A N=51 Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection
Thoracic Injuries
Primary: All Cause Mortality — 4 participants
N/A N=50 Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection
Type B Aortic Dissection
Primary: All-cause Mortality Incidence Through 30 Days Post-treatment — 5 participants — p=.006
Phase 2 N=100 Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma
Blunt Chest Wall Trauma · Rib Fracture · Sternal Fracture
Primary: Opioid Requirement at 24 Hours Post-randomization — 38; 202 morphine milligram equivalents
N/A N=50 TRANSFIX Zenith® Transection Clinical Study
Thoracic Aorta · Thoracic Injuries · Blunt Injuries
Primary: All-cause Mortality — 1 participants
N/A N=10 Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysms
Primary: Freedom From Major Adverse Events (MAE) at Day 30 — 3; 4 Participants
N/A N=50 Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections
Aortic Dissection
Primary: All Cause Mortality. — 4 participants
N/A N=10 GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysm
Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…
N/A N=304 Physician-Sponsored IDE for the Talent Endoluminal Stent Graft System for the Treatment of Thoracic Lesions
Thoracic Aortic Aneurysms · Thoracic Transections · Intramural Hematoma
Primary: Number of Participants With Successful Endoluminal Treatment of Thoracic Lesion — 294 Participants
N/A N=41 Damage Control for Duodenal and Combined Duodenal-Pancreatic Injuries
Injury of Duodenum · Pancreatic Injury
Primary: Duodenal-related Complications — 13; 11; 8; 19 percentage of subjects
N/A N=613 Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair
Abdominal Aortic Aneurysm
Primary: Mortality — 111; 112; 133; 130 Participants
N/A N=61 A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection
Aortic Diseases
Primary: Composite of Partial or No False Lumen Thrombosis, Aortic Rupture, and Aortic Dilatation — 15; 31 participants — p=<0.001
N/A N=30 Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation
Native and Valve in Valve Aortic Valve Failure
Primary: Number of Participants With Procedure Success, Measured at Exit From the Catheterization Laboratory — 28 participants
Phase 2 N=23 GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta
Aortic Aneurysm, Thoracic
Primary: Freedom From Major Adverse Events and Major Device Events Through 1 Year Post-treatment — 11 Participants
N/A N=160 Valor II: The Valiant Thoracic Stent Graft System Clinical Study
Thoracic Aortic Aneurysm
Primary: Percentage of Participants That Did NOT Experience Aneurysm-Related Mortality (Post-market Primary Endpoint) — 94.8 Percentage of participants
N/A N=51 Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic
Aneurysm
Primary: The Number of Subjects Free From a Major Device Event Through 1 Month Post-treatment — 50 participants — p=0.0024
N/A N=132 Biomarkers in Thoracic Aorta Surgery
Aortic Aneurysm · Thoracoabdominal Aneurysm · Aortic Dissection
Primary: Number of Total Postoperative Complications — 69 post-operative complications
N/A N=31 Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms
Aortic Aneurysm, Thoracic
Primary: Number of Participants With Successful Study Device Access — 31 Participants
Phase 4 N=50 Low Dose Ketamine for Blunt Thoracic Trauma
Blunt Injury of Thorax · Multiple Rib Fractures, Involving Three Ribs
Primary: Milligrams of Morphine Equivalents (MME) Administered — 84.9; 81.7 Morphine Milligam Equivalents (MME)
N/A N=21 ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection
Aortic Dissection
Primary: All Cause Mortality at 30 Days Post-procedure — 3 Participants
N/A N=1,366 Endovascular Exclusion of TAAA/AAA Utilizing Fenestrated/Branched Stent Grafts
Thoracoabdominal Aneurysm · Abdominal Aortic Aneurysm
Primary: Freedom From Aneurysm Rupture — 22 Participants
Phase 3 N=100 To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease
Aneurysm, Dissecting · Aortic Aneurysm, Thoracic
Primary: Percentage of Participants With Technically Successful Implant — 99.0 percentage of participants
Phase 4 N=267 BEFAST (Bubble-Enhanced FAST) for the Evaluation of Solid Organ Injury
Abdominal Trauma
Primary: Sensitivity of Detecting Solid Organ Injury Measured as the Number of True Positives — 18; 20 Participants
N/A N=88 Angiotensin II Pathway and Postoperative Hypoxemia
Aortic Dissection
Primary: The Difference Concentrations of ANG II in Serum Between Patients With and Without Postoperative Hypoxemia. — 100; 78.5 pg / mL
N/A N=100 LSA Reconstruction With Laser Fenestration During the TEVAR
Type B Aortic Dissection
Primary: Freedom From All-cause Reintervention, All-cause Mortality and Major Adverse Events Within 30 Days After Procedure — 84 Participants
N/A N=55 CTAG Dissection/Trauma Post Marketing Surveillance Japan
Thoracic Aortic Aneurysm · Thoracic Aorta Injury · Thoracic Aortic Dissection
Primary: Primary Entry Tear Exclusion — 21; 26; 27; 22 Participants
N/A N=9 Early Feasibility of the Branched TAG® Device in the Treatment of Aortic Arch Aneurysms
Aneurysm of Aortic Arch
Primary: Number of Participants With Successful Study Device Access — 9 Participants
N/A N=15 Guo's Visceral Arteries Reconstruction: First in Man Study
Thoracoabdominal Aortic Aneurysm · Pararenal Aortic Aneurysm
Primary: Number of Participants With Major Adverse Events (MAE) Within 30 Days Postoperative — 1 participants
N/A N=105 Coarctation Of the Aorta Stent Trial
Coarctation of the Aorta
Primary: Change in Difference Between Arm and Leg Systolic Blood Pressure From Baseline to 12 Months — 30 mmHg